

1                         UNITED STATES DISTRICT COURT

2                         SOUTHERN DISTRICT OF WEST VIRGINIA

3                         AT CHARLESTON

4

5                         ----- )

6     IN RE:  ETHICON, INC., PELVIC     )Master File

7     REPAIR SYSTEM PRODUCTS             )No. 2:12-MD-02327

8     LIABILITY LITIGATION             )MDL 2327

9                         ----- )

10    THIS DOCUMENT RELATES TO         )JOSEPH R. GOODWIN

11    CAROLYN LEWIS, et al. v.         )U.S. DISTRICT JUDGE

12    ETHICON, INC.                     )

13    Case No. 2:12-CV-04301          )

14                         ----- )

15

16                         The deposition of BRUCE A. ROSENZWEIG,

17                         M.D., called for examination, taken pursuant to the

18                         Federal Rules of Civil Procedure of the United

19                         States District Courts pertaining to the taking of

20                         depositions, taken before JULIANA F. ZAJICEK, CSR

21                         No. 84-2604, a Certified Shorthand Reporter of said

22                         State of Illinois, at the offices of Wexler

23                         Wallace, Suite 3300, 55 West Monroe Street,

24                         Chicago, Illinois, on November 4, 2013, at 9:00 a.m.

25

1 APPEARANCES:  
2 APPEARED ON BEHALF OF THE PLAINTIFFS:  
3 WAGSTAFF & CARTMELL LLP  
4 4740 Grand Avenue, Suite 300  
5 Kansas City, Missouri 64112  
6 816-701-1100  
7 BY: THOMAS P. CARTMELL, ESQ.  
8 tcartmell@wcllp.com;  
9 JEFFREY M. KUNTZ, ESQ.  
10 jkuntz@wcllp.com  
11 -and-  
12 MATTHEWS & ASSOCIATES  
13 2905 Sackett Street  
14 Houston, Texas 77098  
15 713-522-5250  
16 BY: DAVID P. MATTHEWS  
17 dmatthews@dpmlawfirm.com  
18 -and-  
19 AYLSTOCK, WITKIN, KREIS & OVERHOLTZ, PLLC  
20 17 East Main Street, Suite 200  
21 Pensacola, Florida 32502  
22 850-202-1010  
23 BY: RENEE BAGGETT, ESQ. (Telephonically)  
24 rbaggett@awkolaw.com  
25  
26 APPEARED TELEPHONICALLY ON BEHALF OF THE PLAINTIFF  
27 CAROLYN LEWIS:  
28 FREESE & GOSS PLLC  
29 Regions Harbert Plaza 1901  
30 6th Avenue North  
31 Birmingham, Alabama 35203  
32 205-871-4144  
33 BY: CALLE M. MENDENHALL, ESQ.  
34 calle@freeseandgoss.com  
35  
36  
37  
38  
39  
40

1 APPEARED ON BEHALF OF THE DEFENDANTS:

2 BUTLER, SNOW, O'MARA, STEVENS & CANNADA, PLLC

1020 Highland Colony Parkway, Suite 1400

3 Ridgeland, Mississippi 39158-6010

601-948-5711

4 BY: CHRISTY D. JONES, ESQ.

christy.jones@butlersnow.com;

5 PAUL S. ROSENBLATT, ESQ.

paul.rosenblatt@butlersnow.com

6

7

8

9

10 REPORTED BY: JULIANA F. ZAJICEK, CSR No. 84-2604.

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

1 (WHEREUPON, the witness was duly  
2 sworn.)

3 BRUCE A. ROSENZWEIG, M.D.,  
4 called as a witness herein, having been first duly  
5 sworn, was examined and testified as follows:

6 EXAMINATION

7 BY MS. JONES:

8 Q. Doctor, would you state your name and  
9 address for us please, sir?

10 A. Bruce Alan Rosenzweig. My professional  
11 address is 1725 West Harrison Street, Suite 358,  
12 Chicago, Illinois 60612.

13 Q. And, Doctor, you are an  
14 obstetrician/gynecologist by training?

15 A. That is correct.

16 Q. And do I understand correctly that you  
17 are in private practice, in the private practice of  
18 medicine here in Chicago now?

19 A. That is correct.

20 Q. How long have you been in private  
21 practice?

22 A. Well, I -- I started here in Chicago at  
23 the University of Illinois in 1998, I moved to  
24 Mercy Hospital where I was in more of a private  
25 practice than an academic practice, then I moved

1 time and the time that you started working in this  
2 litigation?

3 A. I -- I know I looked at a lot of patent  
4 documents. I don't remember specifically if the  
5 patent infringement case I was working on I saw  
6 510(k) documents. So, I don't want to say yes at  
7 that point, which was also about six or seven years  
8 ago.

9 Q. Have you ever prepared clinical expert  
10 reports?

11 A. No, I have not.

12 Q. Have you ever prepared design history  
13 files?

14 A. No, I have not.

15 Q. Have you ever prepared DFMEAs?

16 A. No, I have not.

17 Q. Have you ever prepared IFUs?

18 A. Well, I did work with Gish Biomedical to  
19 get the information that they needed to put in the  
20 amnioinfusion catheter IFU.

21 Q. Did you actually draft the IFU?

22 A. No, I did not. I worked as a consultant  
23 on that.

24 Q. Have you ever drafted an IFU?

25 A. No, I have not.

1 Q. Have you ever drafted a patient  
2 brochure?

3 A. I worked on the amnioinfusion catheter  
4 brochures, yes.

5 Q. Other than your working as a consultant  
6 with Gish on the IFU and patient brochure on the  
7 IFU, have you ever had any other experience either  
8 as a consultant or drafting an IFU or patient  
9 brochure?

10 A. Yes. I was on EMPI's scientific  
11 advisory committee in the mid-'90s and I know we  
12 worked on various documents like that. I can't --

13 Q. You were on whose scientific advisory  
14 committee?

15 A. EMPI. It is a company in Minnesota that  
16 makes an electrical stimulator for the treatment of  
17 stress incontinence and urge incontinence.

18 Q. And so your role there was?

19 A. An adviser to -- at that point they were  
20 working on doing a prospective randomized  
21 controlled trial because the insurance companies  
22 were looking at this technique as experimental, and  
23 so they needed to get some data in the literature  
24 to show that it wasn't experimental.

25 Q. Have you ever prepared any risk

1 management reports?

2 A. No, ma'am. Well, risk management as far  
3 as medical -- medical products, right?

4 Q. Right.

5 A. Okay. Good.

6 Q. Not in terms of your hospital --

7 A. Patients, doctors, right.

8 Q. -- services and patients and all of  
9 that.

10 Have you ever been an employee or  
11 consultant to the FDA?

12 A. No, I have not.

13 Q. Have you ever served on an FDA advisory  
14 committee meeting?

15 A. No, I have not.

16 Q. Have you ever corresponded with the FDA  
17 with respect to your opinions on anything about a  
18 medical device?

19 A. No, I have not.

20 Q. Have you ever shared with the FDA any of  
21 your opinions that you have included within your  
22 reports marked as Exhibits 2 and 3 here?

23 A. No, I have not.

24 Q. Have you ever published these opinions  
25 in any other form other than in this report marked

1 as Exhibit 2 and 3?

2 A. I think there is some of the I'll call  
3 it factual information in a presentation that I  
4 gave this year about polypropylene degradation and  
5 stuff like that, but that would be the only thing.

6 Q. That would be in one of the --

7 A. Slide decks, yes.

8 Q. -- slide decks?

9 A. Yes.

10 Q. Again, we'll come back to those --

11 A. Excellent.

12 Q. -- in just a second.

13 You don't have any background in polymer  
14 chemistry, do you?

15 A. No, ma'am.

16 Q. You don't consider yourself to be a  
17 biomaterial specialist?

18 A. I have not studied biomaterials, nor do  
19 I have an advanced degree in biomaterials.

20 Q. And I take it it's true that you've  
21 never done any bench research or lab research with  
22 respect to polypropylene?

23 A. Not to polypropylene.

24 Q. Am I correct that you have never advised  
25 the FDA of any of your opinions that you've

1 device report to either the FDA or to Ethicon?

2 A. Yes. I filled out the paperwork for  
3 those.

4 Q. And this was in when?

5 A. 2004, 2005, 2006.

6 Q. On how many occasions?

7 A. I'm going to say at the most five.

8 Q. Were these implants that you had  
9 implanted?

10 A. There was one case that I remember that  
11 I implanted that had an erosion, and I'm pretty  
12 sure I filled out the paperwork with the rep on  
13 that case, but the other ones were ones that were  
14 sent to me.

15 Q. All right. Now, my initial question to  
16 you was degradation --

17 A. That is correct.

18 Q. -- not erosion. So my -- let me go back  
19 and make sure that we are on the same page.

20 Did you report to anyone a finding of  
21 erosion -- of degradation in 2004 or 2005?

22 A. No, ma'am.

23 Q. Have you ever reported that to anyone?

24 A. No, ma'am.

25 Q. Have you ever done any type of

1 pathological analysis on a removed TVT or implant?

2 A. Myself?

3 Q. Yes, sir.

4 A. No, ma'am.

5 Q. Have you ever ordered that one be done?

6 A. I send the explants that I do down to  
7 pathology, so I guess that would be considered  
8 ordering.

9 Q. And they would do whatever their normal  
10 pathological process or procedure is in terms and  
11 then those records would just be included within  
12 the medical records?

13 A. That is correct.

14 Q. Other than that, have you been engaged  
15 in any type of analysis of polypropylene?

16 A. No, ma'am.

17 Q. Have you ever reported to anyone that  
18 you have seen or observed any particle loss from  
19 polypropylene?

20 A. Except to the patient, just to the  
21 patient.

22 Q. Have you ever reported that to the FDA?

23 A. No, ma'am.

24 Q. Have you ever reported it to Ethicon?

25 A. No, ma'am.

1           A.       Those two in specific, no. Just those  
2       two being representative of the body of retropubic  
3       and obturator TVTs.

4 MS. JONES: Let's just take a break and we'll  
5 do that and have lunch, unless you all are all  
6 assuming -- yes, it is one o'clock. You all are  
7 ready for it.

8 MR. CARTMELL: Okay.

11 BY MS. JONES:

12 Q. I'm going to quickly go through a series  
13 of things just to clean up my notes to make sure  
14 I've asked the question.

15 Other than Exhibit 6 which is your  
16 PowerPoint, you never published anything on  
17 polypropylene, is that correct?

18 A. That is correct.

19 Q. You never published anything on the  
20 degradation of polypropylene. is that correct?

21 A. That is correct.

22 Q. You've never done -- never published  
23 anything about the porosity of mesh, correct?

24 A That is correct

25 Q. You never published anything on the

1        cytotoxicity of mesh, correct?

2            A.        That is correct.

3            Q.        You never published anything on fibrotic  
4        bridging, correct?

5            A.        That is correct.

6            Q.        You never published anything on  
7        contracture, correct?

8            A.        That is correct.

9            Q.        You are not a pathologist?

10          A.        I have not done a residency program in  
11        pathology. I am not boarded by the American  
12        Pathological Association.

13          Q.        You are not a polymer chemist?

14          A.        That is correct.

15          Q.        Not an organic chemist?

16          A.        That is correct.

17          Q.        Not a toxicologist?

18          A.        That is correct.

19          Q.        You've done no research and development  
20        with respect to polypropylene?

21          A.        That is correct.

22          Q.        You've never done any examination of a  
23        biomaterial to evaluate tensile strength, for  
24        example?

25          A.        A biomaterial, we did a study on -- on

1 Q. And that information that you've  
2 presented based upon your findings at that time, to  
3 the extent that it was based upon any confidential  
4 documents would have been based upon either Bard or  
5 AMS documents, correct?

6 A. That was not related to any confidential  
7 documents.

8 Q. So there wasn't any confidentiality  
9 associated then with it, was there?

10 A. Well, from -- quite frankly, I err on  
11 the side of I don't know what I can or can't talk  
12 about in this and I prefer not to talk about it so  
13 that I don't have any problems later on.

14 Q. Fair enough.

15 A. Okay.

16 Q. I'm going to skip around a little bit,  
17 so just bear with me to get through with some of  
18 this stuff.

19 You've never performed any pathological  
20 testing on sutures, is that correct?

21 A. I did a pathology rotation when I was a  
22 student and also during residency. We might have  
23 looked at sutures under the microscope. But are  
24 you talking about doing any kind of pathological  
25 stuff?

1 Q. Analysis or study or --

2 A. No.

3 Q. And the same would be true with respect  
4 to mesh or polypropylene in general?

5 A. That is correct.

6 Q. You've never dried or cleaned mesh for  
7 any pathological analysis, correct?

8 A. That is correct.

9 Q. You have never sputter coated an  
10 explanted mesh?

11 A. Have I explanted mesh, yes, I have.

12 Q. No. Have you sputter coated?

13 A. Sputter coated.

14 MR. CARTMELL: It sounds funny.

15 BY THE WITNESS:

16 A. I have explanted mesh. I really do not  
17 remember ever sputter coating the explanted mesh.

18 BY MS. JONES:

19 Q. Have you ever done any differential  
20 scanning calorimetry?

21 A. I don't even think I can pronounce that.

22 Q. Huh?

23 A. No, I have not.

24 Q. How about thermogravimetric analysis?

25 A. No.

1 Q. How about compliance testing to  
2 determine mesh density?

3 A. No.

4 Q. How about any type of oxidative  
5 degradation testing?

6 A. No.

7 Q. Any type of molecular weight  
8 determination?

9 A. No.

10 Q. Any type of uniaxial testing?

11 A. Uniaxial tension testing?

12 Q. Testing.

13 A. Uniaxial would be a tensioning test?

14 Q. Yes.

15 A. Okay. No.

16 Q. Pore size measurement either with or  
17 without load?

18 A. No.

19 Q. Mechanical testing?

20 A. No.

21 Q. Chemical analysis?

22 A. Of what?

23 Q. Of either polypropylene mesh or poly --

24 A. Oh, okay. I mean, I've done a lot of

25 chemical analysis back when I was in chemistry, but

1 not of mesh.

2 Q. Not of mesh, not of polypropylene?

3 A. That is correct.

4 Q. No toxicity or cytotoxicity testing of  
5 polypropylene or mesh?

6 A. That is correct.

7 Q. Have you ever read the FDA regulations  
8 pertaining to polypropylene meshes?

9 A. The FDA regulations regarding what?

10 Q. Polypropylene meshes?

11 A. Regarding what?

12 Q. Anything.

13 A. The -- quite frankly, that is such a  
14 broad question, I don't know how to answer that  
15 question.

16 Q. Well, when is the last time you reviewed  
17 the FDA regulations on medical devices?

18 A. For what?

19 Q. Just for any purpose.

20 A. No, no, I mean for clearing devices, for  
21 the various, you know, components of the device,  
22 like the IFU? That's why I'm having a little bit  
23 of problems.

24 Q. What I'm trying to find out is to what  
25 extent you are going to claim that you are an

1 you would, why it is that you as a surgeon who  
2 performs pelvic surgery has expertise related to  
3 what warnings and adverse reactions need to be in  
4 an IFU?

5 A. Well, I have experience using medical  
6 devices, I have experience determining whether or  
7 not I'm going to use medical devices in my  
8 practice, I have experience determining if a  
9 particular medical device is useful for a specific  
10 patient and then counseling the patient on those  
11 individual -- on the risks associated with a  
12 particular medical device so that that patient can  
13 determine if she wants to have a medical device  
14 either implanted or used to treat her condition.

15 MR. CARTMELL: All right. Thanks. That's all  
16 I have.

17 FURTHER EXAMINATION

18 BY MS. JONES:

19 Q. Doctor, you would agree that any other  
20 urogynecologist or specialist in female pelvic  
21 surgery or treating stress urinary incontinence  
22 would have similar expertise, correct?

23 MR. CARTMELL: Object to the form.

24 BY THE WITNESS:

25 A. I think that doctors have -- that are

1 using the IFU, using it to decide if they are going  
2 to keep it in their -- use a device in their  
3 practice to determine if an individual patient that  
4 device is useful for and then counseling the  
5 patient on the use of that device, the risks and  
6 benefits associated with it, I would say that that  
7 would qualify them as an expert in IFUs.

8 MS. JONES: Thank you. That's all I have.

9 (Time Noted: 4:43 p.m.)

10 FURTHER DEPONENT SAITH NAUGHT.

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25